In conclusion, our observations strongly emphasized MYC inhibition as an auspicious therapy for treating NSCLC by targeting cyclin D1 expression in LCSC-like cells, while the whole underlying mechanism still remains unclear. This evidence concerns the gene MYC and non-small cell lung carcinoma.